181 related articles for article (PubMed ID: 19258204)
1. Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial.
Wieneke H; Conrads H; Wolstein J; Breuckmann F; Gastpar M; Erbel R; Scherbaum N
Eur J Med Res; 2009 Jan; 14(1):7-12. PubMed ID: 19258204
[TBL] [Abstract][Full Text] [Related]
2. Levo-alpha-acetylmethadol (LAAM) versus methadone: treatment retention and opiate use.
Longshore D; Annon J; Anglin MD; Rawson RA
Addiction; 2005 Aug; 100(8):1131-9. PubMed ID: 16042643
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia.
Ritter AJ; Lintzeris N; Clark N; Kutin JJ; Bammer G; Panjari M
Addiction; 2003 Nov; 98(11):1605-13. PubMed ID: 14616187
[TBL] [Abstract][Full Text] [Related]
4. Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. A meta-analysis of the randomized, controlled trials.
Glanz M; Klawansky S; McAullife W; Chalmers T
Am J Addict; 1997; 6(4):339-49. PubMed ID: 9398932
[TBL] [Abstract][Full Text] [Related]
5. LAAM maintenance vs methadone maintenance for heroin dependence.
Clark N; Lintzeris N; Gijsbers A; Whelan G; Dunlop A; Ritter A; Ling W
Cochrane Database Syst Rev; 2002; (2):CD002210. PubMed ID: 12076441
[TBL] [Abstract][Full Text] [Related]
6. Levo-alpha-acetylmethadol (LAAM) versus methadone maintenance: 1-year treatment retention, outcomes and status.
Anglin MD; Conner BT; Annon J; Longshore D
Addiction; 2007 Sep; 102(9):1432-42. PubMed ID: 17697277
[TBL] [Abstract][Full Text] [Related]
7. A randomized, open-label trial comparing methadone and Levo-Alpha-Acetylmethadol (LAAM) in maintenance treatment of opioid addiction.
Wolstein J; Gastpar M; Finkbeiner T; Heinrich C; Heitkamp R; Poehlke T; Scherbaum N
Pharmacopsychiatry; 2009 Jan; 42(1):1-8. PubMed ID: 19153939
[TBL] [Abstract][Full Text] [Related]
8. QTc interval prolongation in patients on long-term methadone maintenance therapy.
Maremmani I; Pacini M; Cesaroni C; Lovrecic M; Perugi G; Tagliamonte A
Eur Addict Res; 2005; 11(1):44-9. PubMed ID: 15608471
[TBL] [Abstract][Full Text] [Related]
9. Levo-alpha-acetylmethadol (LAAM): clinical, research, and policy issues of a new pharmacotherapy for opioid addiction.
Prendergast ML; Grella C; Perry SM; Anglin MD
J Psychoactive Drugs; 1995; 27(3):239-47. PubMed ID: 8594167
[TBL] [Abstract][Full Text] [Related]
10. Relationship between LAAM-methadone preference and treatment outcomes.
White JM; Danz C; Kneebone J; La Vincente SF; Newcombe DA; Ali RL
Drug Alcohol Depend; 2002 May; 66(3):295-301. PubMed ID: 12062464
[TBL] [Abstract][Full Text] [Related]
11. The use of levo-alpha-acetylmethadol (LAAM) in methadone patients who have not achieved heroin abstinence.
Borg L; Ho A; Wells A; Joseph H; Appel P; Moody D; Kreek MJ
J Addict Dis; 2002; 21(3):13-22. PubMed ID: 12094997
[TBL] [Abstract][Full Text] [Related]
12. Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy.
Roy AK; McCarthy C; Kiernan G; McGorrian C; Keenan E; Mahon NG; Sweeney B
Addiction; 2012 Jun; 107(6):1132-9. PubMed ID: 22168435
[TBL] [Abstract][Full Text] [Related]
13. Relative potency of levo-alpha-acetylmethadol and methadone in humans under acute dosing conditions.
Eissenberg T; Stitzer ML; Bigelow GE; Buchhalter AR; Walsh SL
J Pharmacol Exp Ther; 1999 May; 289(2):936-45. PubMed ID: 10215673
[TBL] [Abstract][Full Text] [Related]
14. l-Alpha-acetylmethadol (LAAM): prognostic considerations.
Resnick RB; Orlin L; Geyer G; Schuyten-Resnick E; Kestenbaum RS; Freedman AM
Am J Psychiatry; 1976 Jul; 133(7):814-9. PubMed ID: 937573
[TBL] [Abstract][Full Text] [Related]
15. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts.
Freedman RR; Czertko G
Drug Alcohol Depend; 1981 Nov; 8(3):215-22. PubMed ID: 7327086
[TBL] [Abstract][Full Text] [Related]
16. Symptom complaints of patients maintained on methadone, LAAM (methadyl acetate), and naltrexone at different times in their addiction careers.
Judson BA; Goldstein A
Drug Alcohol Depend; 1982; 10(2-3):269-82. PubMed ID: 7166139
[TBL] [Abstract][Full Text] [Related]
17. Corrected QT interval during treatment with methadone and buprenorphine--relation to doses and serum concentrations.
Stallvik M; Nordstrand B; Kristensen Ø; Bathen J; Skogvoll E; Spigset O
Drug Alcohol Depend; 2013 Apr; 129(1-2):88-93. PubMed ID: 23084592
[TBL] [Abstract][Full Text] [Related]
18. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients: a cross-sectional study.
Peles E; Bodner G; Kreek MJ; Rados V; Adelson M
Addiction; 2007 Feb; 102(2):289-300. PubMed ID: 17222284
[TBL] [Abstract][Full Text] [Related]
19. Acceptability of methadyl acetate (LAAM) as compared with methadone in a treatment program for heroin addicts.
Trueblood B; Judson BA; Goldstein A
Drug Alcohol Depend; 1978 Mar; 3(2):125-32. PubMed ID: 631012
[TBL] [Abstract][Full Text] [Related]
20. Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence.
Chang KC; Huang CL; Liang HY; Chang SS; Wang YC; Liang WM; Lane HY; Chen CH; Stephen Huang SK
J Cardiovasc Electrophysiol; 2012 May; 23(5):527-33. PubMed ID: 22136144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
